AGMB

distress 2/10 · well-funded / low risk

$11.91+3%today-33% from 52w high

agomab.com62 employeesFounded 2017Antwerp, BelgiumBiotechnology

Revenue

pre-revenue

Liquidity

$117M

Runway

2.3 yrs

Shares 1y

—

Price & events

-18.7% over 6M

CatalystRating changeDilutionFinancingdashed = today

+2.7%

-3.3%

-0.3%

+11.3%

—

-18.7%

All

Overview

Market Cap: $406.93M
Volume: 13.65K
52 Week Range: $9.61 – $17.82
Total Shares: 34.17M
Float Shares: 16.41M
Short %: 3.05%
% Held by Insiders: 5.90%
% Held by Institutions: 48.45%
RVOL: 0.13x

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 0

No catalyst news yet.

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 34,167,168 · 1 offerings/1y · 0 PIPEs

2026-02-06424B4offering
2026-01-30EFFECTshelf_effective
2026-01-29F-1/Ashelf_registration
2026-01-16F-1shelf_registration

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

strong buy · target $33 (+175% upside) · 4 analysts

2026-06-22HC Wainwright & Co.Buy
2026-03-03Leerink PartnersOutperform
2026-03-03JP MorganOverweight
2026-03-03Morgan StanleyOverweight

Competitors

none identified